Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
NCT07874815
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also evaluate the efficacy of ensifentrine compared with placebo in improving lung function, improving health related quality of life, and preventing severe exacerbations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pulmonary Disease, Chronic Obstructive
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- November 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Family First Medical Research Center ( Site 4458) · Hialeah Gardens, FL
- Advanced Pulmonary Research Institute ( Site 4427) · Loxahatchee Groves, FL
Indiana · 1
- Velocity Clinical Research ( Site 4464) · Valparaiso, IN
New York · 1
- CHEAR Center LLC ( Site 4407) · The Bronx, NY
South Carolina · 1
- Lowcountry Lung & Critical Care, PA ( Site 4413) · Charleston, SC
Tennessee · 1
- M3 Wake Research, Inc. ( Site 4440) · Chattanooga, TN
Texas · 1
- Victoria Clinical Research Group ( Site 4430) · Victoria, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.